1. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
   Shikha Satendra Singh, 2015, World Journal of Gastroenterology CrossRef
2. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models
   Kate Crawford et al, 2021, Cancer Biology & Therapy CrossRef
3. Oleanolic Acid Suppresses Aerobic Glycolysis in Cancer Cells by Switching Pyruvate Kinase Type M Isoforms
   Jia Liu et al, 2014, PLoS ONE CrossRef
4. Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel
   Bo Jin et al, 2015, Cell Biochemistry and Biophysics CrossRef
5. Evaluation of pH-Sensitive Polymeric Micelles Using Citraconic Amide Bonds for the Co-Delivery of Paclitaxel, Etoposide, and Rapamycin
   Min Jeong Jo et al, 2023, Pharmaceutics CrossRef
6. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
   Tasuku Matsuoka et al, 2014, Cancers CrossRef
7. Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma
   Margaret L Gulley, 2015, Experimental & Molecular Medicine CrossRef
8. Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis
   Hua Li et al, 2018, Oncotarget CrossRef
9. Gastric and Esophageal Cancers
   Armen Parsyan et al, 2014, Translation and Its Regulation in Cancer Biology and Medicine CrossRef
10. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
    G. Roviello et al, 2019, Cancer Chemotherapy and Pharmacology CrossRef
11. Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
    Niranjan Awasthi et al, 2018, Molecular Cancer Therapeutics CrossRef
12. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
    Jing Jing Liu et al, 2019, International Journal of Molecular Sciences CrossRef
13. CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer
    Lyla J. Stanland et al, 2023, Molecular Cancer Research CrossRef
14. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway
    L-J Yuan et al, 2014, Cell Death & Disease CrossRef
15. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions
    Kate Young et al, 2016, Drugs CrossRef
16. Current and Future Therapies for Advanced Gastric Cancer
    Michael Davidson et al, 2015, Clinical Colorectal Cancer CrossRef
17. Combining PI3K/Akt/mTOR Inhibition With Chemotherapy
    Albert A. De Vera et al, 2019, Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy CrossRef
18. Senescence-related genes define prognosis, immune contexture, and pharmacological response in gastric cancer
    Xiaogang Shen et al, 2023, Aging CrossRef
19. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
    Md Sazzad Hassan et al, 2023, Biomedicines CrossRef
20. Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric Cancer Cells
    Mi-Young Kim et al, 2019, Molecules and Cells CrossRef
21. Carotenoids as modulators of the PI3K/Akt/mTOR pathway: innovative strategies in cancer therapy
    Biswajit Kumar Utpal et al, 2024, Medical Oncology CrossRef
22. Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
    Kamelia Hashemzadeh et al, 2018, Middle East Journal of Digestive Diseases CrossRef
23. Phytochemicals and Nanoparticles in the Modulation of PI3K/Akt/mTOR Kinases and its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence
    Arunaksharan Narayanankutty et al, 2023, Recent Patents on Anti-Cancer Drug Discovery CrossRef
24. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions
    Ayda Baghery Saghchy Khorasani et al, 2021, European Journal of Pharmacology CrossRef